An Australian consensus statement for the management of HCC was also published with a high level of agreement on using liver ultrasound with or without the combination of AFP at 6-month intervals for HCC surveillance with high-risk populations [21]. The gene discussed is AFP; the disease is hepatocellular carcinoma.